| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b6477293d1997a95f7a71c8c26a16c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8b830e50a16c4ef3e40f578f280fae1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb32a5276e7599bb0f6ef219916f68a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c3d76288892ddbddca3e1fe2313ec5c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate |
2009-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb8070ac51123034cd8ad74a2ee61813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55a50e39cab28f97971a8837e8a28bde
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2eeaa82e6113aae473d537edc06a4cfe |
| publicationDate |
2010-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010066112-A1 |
| titleOfInvention |
siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION |
| abstract |
No antiviral regimen has been consistently successful in treating H5N1 virus infection. We demonstrate that a group of highly effective siRNAs targeting different H5N1 viral genes shares a unique motif, GGAGU/ ACUCC. We further demonstrate that the effectiveness of siRNAs containing this motif is not sequence specific. The results suggested that the structure of the unique motif is critical in determining the potency of siRNA-mediated protective effects against viral infection and this potent in vivo protection is associated with early productions of β-defensin and IL-6 induced by the motif. Provided are methods and prophylactic and therapeutic agents useful against other viral infections in addition to the H5N1 influenza virus. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2639559-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016520052-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2994481-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101800951-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9822155-B2 |
| priorityDate |
2008-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |